CClinicalTrials.gg
CompletedNCT03531151MRIMIUpdated Sep 8, 2025

MRI of Myocardial Infarction

An observational study in Myocardial Infarction, Myocardial Ischemia and Myocardial Injury, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by University of Pennsylvania · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
14
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Heart failure (HF) is an enormous health burden affecting approximately 5.1 million people in the US and is the cause of 250,000 deaths each year. Approximately 50% of HF is caused by myocardial ischemia and requires immediate restoration of coronary blood flow to the affected myocardium. However, the success of reperfusion is partly limited by intramyocardial hemorrhage, which is the deposition of intravascular material into the myocardium. Hemorrhagic reperfusion injury has high prevalence and patients have a much greater risk of adverse left ventricular remodeling, risk of fatal arrhythmia, impaired systolic function and are hospitalized at a greater rate. Recent magnetic resonance imaging techniques have improved assessment of reperfusion injury, however, the association between MRI contrasts and reperfusion injury is highly unclear, and lacks specificity to IMH. Improved imaging of IMH and accurate knowledge about its spatial and temporal evolution may be essential for delivery of optimal medical therapy in patients and critical to identify patients most at risk for adverse ventricular remodeling. The overall goal is to investigate the magnetic properties of hemorrhage and develop MRI techniques with improved specificity to hemorrhage. New MRI techniques permit noninvasive assessment of the magnetic susceptibility of tissues and can target tissue iron. Therefore, the investigators hypothesize that MRI imaging of myocardial magnetic susceptibility can map hemorrhagic myocardium. The investigators will perform a longitudinal observational study in patients after reperfusion injury to validate these methods, compare the methods with conventional MR contrasts and develop MR methods for imaging humans.

02

Conditions studied

  • Myocardial Infarction
  • Myocardial Ischemia
  • Myocardial Injury
  • Myocardial Fibrosis
  • Myocardial Reperfusion Injury
  • Myocardial Edema
  • Myocardial Necrosis
  • Heart Failure
  • Ischemic Heart Disease
  • Ischemic Cardiomyopathy
  • Hemorrhage
03

In context

Myocardial Infarction

2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.

This study's enrollment of 14 is below the median of 500 across 983 observational studies indexed under Myocardial Infarction.

Browse Myocardial Infarction studies →

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,635 studies on the registry; 239 are open to participants now.

Of its 154 completed or terminated interventional studies of FDA-regulated products, 104 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population specific to this project are ST-elevated myocardial infarction (STEMI) patients being treated with reperfusion therapy.

Inclusion criteria

  • Between the ages of 18 and 80
  • Patients must be able to read and understand English
  • Participants must sign the informed consent form
  • Elevated and delayed peak creatine kinase-MB and troponin I (cTnI) and troponin T (cTnT) in blood serum,
  • ST elevation detected on ECG

Exclusion criteria

Exclusion Criteria:

  • contraindications to cardiac MRI, including claustrophobia
  • advanced renal disease (estimated glomerular filtration rate 30 mL/min) or hypersensitivity to gadolinium
  • presence of a cardiac pacemaker or implanted cardiac cardioverter defibrillator
  • pregnancy
  • personal or family history of hypertrophic cardiomyopathy
  • inability to provide informed consent
  • history of seizure disorder
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
14 participants (actual)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. ejection fraction

    Time frame: <36 hours to >6 months

Secondary outcomes

  1. relaxation times

    Time frame: <36 hours to >6 months

  2. extracellular volume fraction

    Time frame: <36 hours to >6 months

07

Study locations

1 site
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03531151
Lead sponsor
University of Pennsylvania
Responsible party
Sponsor
First posted
May 21, 2018
Start date
Apr 1, 2018
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025
Last update
Sep 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion